Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 170 of the 173 references it cites were found in a registry or an index.

Latest approaches for the treatment of obesity

Abstract

Introduction Obesity is a body weight disorder characterized by excess adiposity that increases the risk for developing co-morbidities such as type 2 diabetes. A large medical need exists for new anti-obesity treatments capable of promoting 10% or greater weight loss, with minimal side effects. Areas covered The authors describe the application of monogenic forms of rare obesity and genome-wide association studies in selecting critical pathways for drug discovery. Furthermore, they review in detail several pathways and pharmacological targets in the central nervous system (e.g., the leptin-melanocortin axis, the opioid system, GLP-1/GLP-1 system, and FGF21/FGFR1c/β-Klotho axis) that play an important role in the regulation of feeding behavior and energy homeostasis. Special focus is given to new strategies that engage well-known targets via novel mechanisms in order to circumvent issues seen with previous drug candidates that failed in the clinic. Finally, the authors discuss the recent developments around fixed-dose combinations, targeted polypharmacology, and non-traditional combinations of drugs and devices. Expert opinion The future for new weight-loss approaches to treat obesity looks promising. Current therapies have shown modest effects on weight loss in the general obese population but will have greater impact in smaller homogeneous sub-populations of obese subjects using personalized medicine. Drug combinations that target multiple, complementary pathways have the po…

Overview

Integrity signals

Registry

Crossref · 10.1517/17460441.2015.1044966

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 173 references

Research works printed but not linked: 13

  1. Shin JH, 2013, Diabetes Metab Syndr Obes, 6, 131
  2. 10.1371/journal.pgen.1000508 · DOI · Paper page
  3. Ravussin Y, 2011, Am J Physiol, 300, R1352
  4. 10.1210/jcem.87.5.8628 · DOI · Paper page
  5. 10.1210/endo.143.3.8669 · doi:10.1210/endo.143.3.8669 · Paper page
  6. Clemmensen C, 2015, EMBO Mol Med
  7. Fang S, 2015, Nat Med
  8. Psichas A, 2014, Int J Obes
  9. Chambers ES, 2014, Gut
  10. Allison C, 2006, Issues Emerg Health Technol, 1
  11. 10.1371/journal.pone.0049345 · DOI · Paper page
  12. 10.1124/jpet.113.204420 · DOI · Paper page
  13. 10.1126/scitranslmed.3004690 · DOI · Paper page

Cited by

See all 132

Metadata

Authors
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A.
Affiliations
Pfizer (United States) (US)
Venue
Expert Opinion on Drug Discovery
Published
2015-05-12
Volume
10
Issue
8
Pages
825-839
ISSN
  • 1746-0441 (ISSN-L)
  • 1746-045X
OpenAlex
W2100482349
Cited by
132
References
173
Citations by year
2026: 5 · 2025: 25 · 2024: 18 · 2023: 22 · 2022: 22 · 2021: 17 · 2020: 7 · 2019: 4 · 2018: 5 · 2017: 1 · 2016: 5 · 2015: 1
FWCI
0.50
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
obesity treatment, anti-obesity drugs, monogenic obesity, genome-wide association study, opioid system, GLP-1 receptor, feeding behavior, energy homeostasis, fixed-dose combination, drug-device combination products, personalized medicine, subcutaneous drug delivery, weight loss
MeSH terms
Animals, Drug Therapy, Combination, Humans, Obesity, Drug Design, Weight Loss, Anti-Obesity Agents, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Latest approaches for the treatment of obesity. https://app.cochat.ai/papers/10.1517/17460441.2015.1044966
The paper
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015). Latest approaches for the treatment of obesity. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2015.1044966

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.